Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0847097 (
acidity
)
15,165
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cancer chemotherapy often fails due to acquired drug resistance. One of the most critical biochemical changes observed in drug-resistant tumor cells is over-expression of
glutathione S-transferase
Pi isozyme (GSTP1). Glutathione S-transferase inhibitors have been used as potentiating agents of chemotherapeutic drugs. Earlier we reported haloenol lactone 1 as a site-directed GSTP1 inactivator. We proposed that enzymatic hydrolysis of the haloenol lactone may be the initial step of GSTP1 chemical modification, resulting in the inactivation of the enzyme. Enzyme inactivation is initiated through addition of Cys-47 to the lactone ring, which is opened in the process to form an alpha-bromoketone adduct. The
acidity
of Cys-47 confers good leaving group properties, and rapid hydrolysis occurs to generate an alpha-bromoketoacid intermediate. The reaction may proceed via alkylation of the transient thioester to form a six-membered ring episulfonium ion intermediate which would be yet more reactive toward hydrolysis, with either process leading to the observed mass increase of 230 Da. To probe the importance of the bromine of the lactone in GST inactivation, we designed and synthesized compound 2. Unlike lactone 1, lactone 2 did not show time-dependent inhibitory effect on GSTP1. Incubation of compounds 1 and 2 with excess of N-acetyl cysteine produced the corresponding di-N-acetyl cysteine conjugate and mono-N-acetyl cysteine conjugate, respectively. To probe the role of Cys-47 in the inactivation of GSTP1 by compound 1, we prepared mutant C47A GSTP1. The mutant GSTP1 still showed good activity toward CDNB, but it lost susceptibility to the inactivation by compound 1. In addition, LC-MS/MS technique allowed us to identify the modified Cys-47 after the enzyme was exposed to compound 1.
...
PMID:Mechanistic studies of inactivation of glutathione S-transferase Pi isozyme by a haloenol lactone derivative. 1678 14
Helicobacter pylori has to counteract
acidity
during colonization in the stomach. The most important region for the enzymic activity of H. pylori urease, consisting of 138 aa (ureB138), was determined by a comparison of the homology of amino acid sequences, and a structural analysis, between urease of H. pylori and various other species. This region was expressed in Escherichia coli as a fusion protein with
glutathione S-transferase
(
GST
), which was cleaved by PreScission protease between the
GST
moiety and ureB138. The ureB138 protein was then purified by gel filtration. The polyclonal antibody (pAb) induced by immunization with the purified ureB138 could suppress urease activity by about 50 %, while the pAb against the H. pylori urease did not show any inhibitory effect at all. Immunohistochemical analysis indicated that the ureB138-specific pAb specifically recognized the H. pylori infecting human gastric tissues. The effects of vaccination of recombinant ureB138 against infection by this organism were also examined. Specific IgG and IgA antibodies against H. pylori urease were induced in the serum of mice immunized with ureB138. A reduction in the number of colonizing H. pylori was observed in mice treated with ureB138 compared to ones treated with BSA and infection control mice. In the protected mice, severe gastritis characterized by marked infiltration of mononuclear cells was noted compared with the gastritis observed in unprotected mice. Immunohistochemical staining for IgA in gastric mucosa showed that the number of mice positively stained with IgA was significantly higher in ureB138-vaccinated mice than in non-vaccinated mice. This indicates that local IgA antibody and severe post-immunization gastritis correlate well with the protection of mice against H. pylori infection.
...
PMID:Effects of vaccination by a recombinant antigen ureB138 (a segment of the beta-subunit of urease) against Helicobacter pylori infection. 1751 Feb 73